A reflection on paradigmatic tensions within the FDA advisory committee for MDMA-assisted therapy. [PDF]
Roseman L.
europepmc +1 more source
The relationship between 3,4-methylenedioxymethamphetamine (MDMA) use in young adulthood and anxiety or depressive disorders in the mid-30s: Findings from the Victorian Adolescent Health Cohort Study. [PDF]
Bryant Z +4 more
europepmc +1 more source
3-CMC: Acute Effects in Male and Female Mice, Human Intoxication Case Series (Italy, 2014-2025), and Prediction of ADMET Properties. [PDF]
Bassi M +10 more
europepmc +1 more source
Review of Selected 2-Phenylethylamine Derivatives and Opioids, Systematic Review of Their Effects on Psychomotor Abilities and Driving Performance: Psychopharmacology in the Context of Road Safety. [PDF]
Żełabowski K +11 more
europepmc +1 more source
A neurocognitive account of complex PTSD: self-modelling, affective dysregulation, and implications for MDMA-assisted and targeted psychotherapies. [PDF]
Gerrans P +3 more
europepmc +1 more source
Five cases of unintentional exposure to BZO-4en-POXIZID among nightclub attendees in New York City. [PDF]
Palamar JJ, Massano M, Salomone A.
europepmc +1 more source
Risk communication about high-dose MDMA: Impact of a hypothetical drug alert on future MDMA use. [PDF]
Keygan J +4 more
europepmc +1 more source
Large-scale brain connectivity changes following the administration of lysergic acid diethylamide, d-amphetamine, and 3,4-methylenedioxyamphetamine. [PDF]
Avram M +12 more
europepmc +1 more source
MDMA-assisted psychotherapy for AUD: Bayesian analysis of WHO drinking risk level and exploratory analysis of drinking behavior and psychosocial functioning at 3 months follow-up. [PDF]
Thurgur H +8 more
europepmc +1 more source
Methylenedioxymethamphetamine is a connectogen with empathogenic, entactogenic, and still further connective properties: It is time to reconcile "the great entactogen-empathogen debate". [PDF]
Stocker K, Liechti ME.
europepmc +1 more source

